Publications by authors named "KIMBALL A"
Background: Hidradenitis suppurativa (HS) affects different patient populations that require unique considerations in their management. However, no HS guidelines for these populations exist.
Objective: To provide evidence-based consensus recommendations for patients with HS in 7 special patient populations: (i) pregnancy, (ii) breastfeeding, (iii) pediatrics, (iv) malignancy, (v) tuberculosis infection, (vi) hepatitis B or C infection, and (vii) HIV disease.
Background: SUNSHINE and SUNRISE demonstrated sustained clinical efficacy of secukinumab in patients with moderate-to-severe hidradenitis suppurativa (HS) through 52 weeks. Patients completing the core trials could enter a 4-year extension trial.
Objectives: To evaluate the long-term efficacy, safety/tolerability, and maintenance of clinical response of secukinumab through Week 104 in the extension trial.
Article Synopsis
- Menstrually related mood disorder (MRMD) is characterized by severe emotional symptoms occurring in the late luteal phase of the menstrual cycle, which may be linked to low levels of the neuroactive steroid allopregnanolone due to lesser conversion from progesterone.
- In a study with nine women with MRMD and fourteen healthy controls, MRMD was diagnosed using the DSM-5 criteria, and symptoms of depression and anxiety, as well as plasma neuroactive steroid levels, were assessed at different phases of the menstrual cycle.
- Results showed that while women with MRMD had higher allopregnanolone levels in the mid-follicular phase, they experienced greater depression severity only in the late luteal phase, suggesting a
Introduction: Hidradenitis suppurativa (HS) is a debilitating, inflammatory skin disorder. Treatment strategies in patients with HS are challenging; real-world evidence in a HS population is warranted for greater disease understanding. The objective of this analysis was to describe real-world treatment patterns and treatment satisfaction in patients with HS.
View Article and Find Full Text PDFObjective: Explore the caregiver experience of communicating about differences of sex development (DSD) with their children. Evidence-based guidance regarding how, when, and what information is shared by caregivers is lacking and is needed to inform optimal information sharing strategies for this population.
Methods: Qualitative semi-structured interviews were conducted with 15 caregivers of children with DSD, recruited from 3 multidisciplinary DSD clinics.
Article Synopsis
- * Researchers used advanced LC-MS/MS assays to test whether higher serum myostatin levels correlate with lower insulin sensitivity in 74 overweight/obese adults aged 20-65 without type 2 diabetes.
- * The findings revealed that higher serum myostatin levels were linked to lower insulin sensitivity (Matsuda index) even after accounting for factors like BMI and sex, suggesting myostatin might play a role in the development of insulin resistance.
Article Synopsis
- Hidradenitis suppurativa (HS) is a long-term skin disease that's tough to manage and treat.
- Biologics and small targeted molecules are being explored as potential treatments for moderate-to-severe HS, with only three approved by FDA or EMA: adalimumab, secukinumab, and bimekizumab.
- Ongoing research is focusing on new agents that target various inflammatory pathways, including interleukin 17A/F and the JAK/STAT pathway.
Gender Equity and Academic Dermatology: Are we giving the right advice?
J Eur Acad Dermatol Venereol
August 2024
Background And Objective: Upadacitinib is indicated for diseases affecting persons of childbearing potential including rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, atopic dermatitis, Crohn's disease, and ulcerative colitis; however, teratogenicity was observed in animal studies. Given the potential for human fetal risk, pregnancy avoidance measures were required during clinical trials. This analysis describes pregnancy outcomes in patients exposed to upadacitinib during pregnancy.
View Article and Find Full Text PDFVery little is known about the process of meiosis in the apicomplexan parasite Cryptosporidium despite the essentiality of sex in its life cycle. Most cell lines only support asexual growth of Cryptosporidium parvum (C. parvum), but stem cell derived intestinal epithelial cells grown under air-liquid interface (ALI) conditions support the sexual cycle.
View Article and Find Full Text PDFBackground: In some hidradenitis suppurativa (HS) clinical trial study arms, there is an unexpected decline in efficacy between the penultimate visit and the prespecified primary endpoint week, which we have termed a "wobble."
Objective: We aimed to establish how often study arms in HS programs wobble.
Methods: In a retrospective review, we identified HS clinical trials listed on ClinicalTrials.
Article Synopsis
- Bimekizumab, a monoclonal antibody targeting IL-17F and IL-17A, is being tested as a treatment for moderate-to-severe hidradenitis suppurativa, a condition with limited treatment options.
- The BE HEARD I and II trials were 48-week, randomized, double-blind studies that evaluated the efficacy and safety of various dosing regimens of bimekizumab compared to a placebo in over 1,000 patients.
- Results showed significant improvement in patients receiving bimekizumab every 2 weeks, meeting the primary efficacy goal of at least a 50% reduction in disease symptoms by week 16.
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with a considerable disease burden. Existing treatment options are limited and often suboptimal; a high unmet need exists for effective targeted therapies.
Objectives: To explore the effects of spesolimab treatment in patients with HS.
Very little is known about the process of meiosis in the apicomplexan parasite despite the essentiality of sex in its life cycle. Most cell lines only support asexual growth of (), but stem cell derived intestinal epithelial cells grown under air-liquid interface (ALI) conditions support the sexual cycle. To examine chromosomal dynamics during meiosis in , we generated two transgenic lines of parasites that were fluorescently tagged with mCherry or GFP on chromosomes 1 or 5, respectively.
View Article and Find Full Text PDFBACKGROUND: Hidradenitis suppurativa (HS) is a debilitating, inflammatory skin disease with limited treatment options and partially understood pathophysiology. Using an umbrella trial design, three kinase inhibitor immunomodulators with different mechanisms of action were evaluated. METHODS: This phase 2a, double-blind, parallel-group trial enrolled adults with moderate to severe HS who were then randomly assigned (1:1:1:1) to once-daily brepocitinib 45 mg (a JAK1/TYK2 inhibitor), zimlovisertib 400 mg (an IRAK4 inhibitor), ropsacitinib 400 mg (a TYK2 inhibitor), or matching placebo for 16 weeks.
View Article and Find Full Text PDFBackground: Females and minorities have been underrepresented in clinical research despite legislative efforts, including in hidradenitis suppurativa (HS) and psoriasis (PsO) clinical trials.
Objective: To identify differences in demographic breakdowns of HS and PsO patients between health care settings to uncover any causative health disparities.
Methods: This study reports racial, ethnic, and sex of HS and PsO patient populations across the emergency department (ED), inpatient, clinical trial, and registry settings.
Burden of Hidradenitis Suppurativa: A Systematic Literature Review of Patient Reported Outcomes.
Dermatol Ther (Heidelb)
January 2024
Introduction: Hidradenitis suppurativa (HS) has a profound negative impact on patients' health-related quality of life (HRQoL). Here we summarize the evidence on HRQoL and Patient Reported Outcomes (PROs) in patients with HS in real-world settings by conducting a systematic literature review (SLR) of observational studies.
Methods: Data sources included MEDLINE, Embase & PsycINFO between January 1, 2010 and August 29, 2021, and conference proceedings between 2019 and 2021.
Article Synopsis
- Transgender individuals, especially transgender women (TGW) and transgender men (TGM), face a higher risk of HIV but commonly have low rates of preexposure prophylaxis (PrEP) usage, despite clinical visits for gender-affirming hormone therapy (GAHT) being potential chances for HIV prevention.
- A study analyzed data from 2014 to 2021, revealing an increase in transgender diagnosis codes and GAHT prescriptions, with notable HIV testing and PrEP usage among insured TGW (61.1% tested, 20.2% on PrEP) and TGM (48.3% tested, 10.2% on PrEP).
- The research highlights the need to recognize transgender individuals in